ERBB2 and breast carcinoma: For example, in the PHERGain phase 2 randomized clinical trial, patients with HER2-positive breast cancer who demonstrated a metabolic response on mid-treatment PET scans were able to safely omit chemotherapy and receive exclusive dual HER2 blockade, without compromising invasive disease-free survival [9].